Announcement of New Shares through Third-Party Allocation

Feb 21, 2018

Jiksak Bioengineering secures 170 million JPY from ANRI, OHARA Pharma, Essential Pharma, and MediFuture to commercialize the Nerve Organoid Chip and further develop its regenerative medicine business.